Jagsonpal Pharmaceuticals Limited

NSE JAGSNPHARM.NS

Jagsonpal Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2024: USD 0.10

Jagsonpal Pharmaceuticals Limited EPS (Diluted) is USD 0.10 for the year ending March 31, 2024, a -18.27% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Jagsonpal Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2023 was USD 0.12, a 30.88% change year over year.
Jagsonpal Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2022 was USD 0.09, a 6.66% change year over year.
Jagsonpal Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2021 was USD 0.09, a 123.33% change year over year.
Jagsonpal Pharmaceuticals Limited EPS (Diluted) for the year ending March 31, 2020 was USD 0.04, a 0.60% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NSE: JAGSNPHARM.NS

Jagsonpal Pharmaceuticals Limited

CEO	Mr. Manish Gupta
IPO Date	July 1, 2002
Location	India
Headquarters	T-210 J, Shahpur Jat
Employees	1,025
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.

Key trends

Past 5 years